Stemline Therapeutics (NASDAQ:STML) Price Target Cut to $8.00 by Analysts at JPMorgan Chase & Co.

Stemline Therapeutics (NASDAQ:STML) had its price objective lowered by equities researchers at JPMorgan Chase & Co. from $9.00 to $8.00 in a research report issued to clients and investors on Thursday, BenzingaRatingsTable reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 86.05% from the stock’s current price.

Several other research firms have also recently weighed in on STML. ValuEngine raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 21st. Piper Sandler lowered their price target on Stemline Therapeutics from to in a report on Tuesday, March 17th. Wedbush lowered their price target on Stemline Therapeutics from $14.00 to $11.00 and set an “outperform” rating on the stock in a report on Tuesday, March 17th. BidaskClub cut Stemline Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 10th. Finally, HC Wainwright lowered their price target on Stemline Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $15.56.

Shares of NASDAQ STML traded up $0.06 during midday trading on Thursday, hitting $4.30. 37,783 shares of the stock traded hands, compared to its average volume of 970,498. The firm has a 50-day moving average of $5.80 and a two-hundred day moving average of $8.74. The firm has a market capitalization of $223.16 million, a P/E ratio of -2.25 and a beta of 1.44. Stemline Therapeutics has a one year low of $3.21 and a one year high of $18.22.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, March 13th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.01. The firm had revenue of $11.83 million for the quarter, compared to analysts’ expectations of $11.82 million. Stemline Therapeutics had a negative return on equity of 56.00% and a negative net margin of 177.74%. On average, equities analysts anticipate that Stemline Therapeutics will post -1.29 earnings per share for the current year.

In other news, CEO Ivan Bergstein sold 24,642 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $6.42, for a total value of $158,201.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Kenneth Hoberman sold 13,228 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $10.37, for a total value of $137,174.36. The disclosure for this sale can be found here. Insiders sold a total of 125,289 shares of company stock valued at $815,230 over the last 90 days. 13.10% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Eventide Asset Management LLC increased its stake in shares of Stemline Therapeutics by 30.3% in the 3rd quarter. Eventide Asset Management LLC now owns 4,160,608 shares of the biopharmaceutical company’s stock worth $43,312,000 after purchasing an additional 967,881 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Stemline Therapeutics by 2.2% in the 4th quarter. Farallon Capital Management LLC now owns 2,350,000 shares of the biopharmaceutical company’s stock worth $24,981,000 after purchasing an additional 50,000 shares in the last quarter. State Street Corp increased its stake in Stemline Therapeutics by 7.5% in the 4th quarter. State Street Corp now owns 2,160,745 shares of the biopharmaceutical company’s stock worth $22,969,000 after buying an additional 151,149 shares in the last quarter. Alliancebernstein L.P. increased its stake in Stemline Therapeutics by 17.1% in the 4th quarter. Alliancebernstein L.P. now owns 1,883,518 shares of the biopharmaceutical company’s stock worth $20,022,000 after buying an additional 274,433 shares in the last quarter. Finally, Sectoral Asset Management Inc increased its stake in Stemline Therapeutics by 51.0% in the 4th quarter. Sectoral Asset Management Inc now owns 1,023,159 shares of the biopharmaceutical company’s stock worth $10,876,000 after buying an additional 345,400 shares in the last quarter. Hedge funds and other institutional investors own 81.86% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: What is Blockchain?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.